CAS Medical Systems, Inc. Announces Children’s National Medical Center Participation in its “Center of Excellence” Program
FORE-SIGHT® Cerebral Oximeters Sold to Children’s National for Use in Neonatal Intensive Care Unit
Branford, Conn. October 14, 2008 CAS Medical Systems, Inc. (NASDAQ: CASM), a leader in noninvasive monitoring that is vital to patient care, today announced that Children’s National Medical Center in Washington, DC will participate in CASMED’s Center of Excellence Program. The hospital has also purchased FORE-SIGHT Cerebral Oximeters for use in its Neonatal Intensive Care Unit (NICU).
Children’s National is ranked among the top ten pediatric hospitals for neonatal care in America by U.S. News & World Report. Children’s National is the only exclusive provider of pediatric care in the Washington metropolitan area, and is the only freestanding children’s hospital between Philadelphia, Pittsburgh, Norfolk, and Atlanta. Serving the nation’s children for more than 135 years, Children’s National is a proven leader in developing and providing innovative new treatments for childhood illness and injury. Children’s National Medical Center features 283 beds, 48 of which are Level IIIC NICU basinets, a Cardiac Intensive Care Unit, and a Neuro Intensive Care Unit.
As a participant in the Center of Excellence Program, Children’s National will work with CASMED to develop protocols and conduct research regarding the use of cerebral oximetry in the hospital. In addition, Children’s National will act as a reference site, and as a beta testing center, for the FORE-SIGHT monitor and sensor products.
Dr. Billie Lou Short, M.D., chief of the Division of Neonatology at Children’s National, stated, “Clinicians and researchers at Children’s National Medical Center in the Division of Neonatology have worked closely with the research and development team at CASMED for several years. The Children’s National team, through this collaboration, conducted clinical studies using the CASMED FORE-SIGHT monitor, verifying the accuracy of the NIRS measurements in a clinical setting. This collaborative effort represents a true bench-to-bedside approach to neuromonitoring equipment development.”
Andrew E. Kersey, President and CEO of CASMED, said, “Our Center of Excellence Program will provide a network of customers and thought leaders that can help expand the use of our superior cerebral oximetery technology as a standard of care, and help guide CASMED in the development of future and next generation products. CASMED is pleased to partner with Children’s National and to have their support as we seek to help improve neonatal care and to be a leader in creating innovative solutions to pediatric healthcare problems.”
About CASMED® - Monitoring What’s Vital
CAS Medical Systems, Inc. is a leading developer and manufacturer of medical devices for non-invasive patient monitoring. The Company’s FORE-SIGHT Absolute Cerebral Oximeter is the only cerebral oximeter available with FDA clearance for non-invasive, continuous measurement of absolute cerebral tissue oxygen saturation for neonates, infants, children and adults. This information helps avert brain damage or death during surgery and in critical care situations by allowing clinicians to identify patients with dangerously low levels of cerebral oxygen and intervene to reverse the condition.
The Company’s product lines include the high-acuity monitoring capabilities of the FORE-SIGHT Cerebral Oximeter, the bedside patient monitoring line of vital signs and cardio-respiratory monitoring products, proprietary non-invasive blood pressure measurement technology, and supplies and service including blood pressure cuffs and products for neonatal intensive care. CASMED products are designed to meet the needs of a full spectrum of patient populations worldwide, ranging from adults to pediatrics and neonates.
For further information regarding CAS Medical Systems, Inc., visit the Company’s website at www.casmed.com.
Statements included in this press release, which are not historical in nature, are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements relating to the future financial performance of the Company are subject to many factors including, but not limited to, the customer acceptance of the products in the market, the introduction of competitive products and product development, commercialization and technological difficulties, the impact of actions and events involving key customers and vendors, and other risks detailed in the Company’s Form 10-K for the year ended December 31, 2007 and other subsequent Securities and Exchange Commission filings.
Such statements are based upon the current beliefs and expectations of the Company’s management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. When used in this press release the terms "anticipate", "believe", "estimate", "expect", "may", "objective", "plan", "possible", "potential", "project", "will" and similar expressions identify forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof, and we do not undertake any obligation to update any forward-looking statements, whether as a result of future events, new information or otherwise.
# # #